Observational Healthcare Databases

How it works

Risks & contraindications

Evidence quality

Where it comes from

Highlighted claims

• Nine databases were used, spanning the USA, Europe, Japan, and Australia, covering January 2000 through June 2023. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• All databases were standardised to the OMOP Common Data Model version 5.3 to enable consistent replication across sources. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• Across all databases, 1.2 million BP-CCB initiators and 9.3 million NP-CCB initiators were identified before matching, with 881,758 remaining in each group after matching. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• Residual confounding from unavailable socioeconomic and behavioural variables cannot be ruled out. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• Outcome definitions relied mainly on diagnosis codes, and validity of claims-based algorithms can vary depending on code choice and logic. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study